Evonik advances biotech investments

Evonik says that it plans to continue expanding its commitment to biotech as explores opportunities for profitable growth in a range of business areas. Biotech gives "Evonik's growth strategy a stronger focus on sustainable development. In the health and nutrition business unit alone we are hoping for sales of €1 billion ($1.29 billion) over the medium term for products made using biotech," says Patrik Wohlhauser, member of Evonik's executive board. Evonik will be investing about €350 million by 2014 to expand its Biolys business, an amino...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers